Life Science Nation Newsletter  | September 29,  2016  |  Issue 181

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Sept. 22  - Sept. 28)
Makes Early Stage Deals in Therapeutics, Devices and Diagnostics
Seeks Digital Medicine Devices and Wearables in Chronic Care
Invests in US Therapeutics and Devices at Series A and B
Opens US Office To Invest In Oncology, Opthalmology & Platform Technologies
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI on MaRS Investors Panel

By Dennis Ford, Founder & CEO, LSN

Biotech and medtech industry executives are already drawing up their itineraries for January's healthcare conference week in San Francisco. It's on track to be a busy week for us all. Among the many events and receptions taking place, the Redefining Early Stage Investments Conference (RESI SF) stands alone in providing a targeted opportunity for early stage biotech and medtech companies to schedule up to 16 face-to-face investor meetings in one venue, with the potential for many more ad-hoc investor discussions throughout the day.

Partnering is RESI's core, but at RESI SF also provides a full day of investor panels and workshops devoted to early stage life science investment topics. We'll see the return of the RESI Asia-North America track, with content for entrepreneurs who are looking to the Asia Pacific region as a source of investment or future customers. RESI will also feature sessions focused on investors in each main life science technology vertical, and on key investor categories including Family Offices, Angels and Big Pharma, and a new session on Tech Giants in Healthcare.

With a full day of content and meetings, we're on course for another sellout San Francisco RESI event. Don't leave it too late to get your ticket...

By Lucy Parkinson, Director of Research, LSN

LSN's research staff continue to inverview life science investors from all over the world and collect in depth information on each investor's unique parameters and focus areas. In this article, we'll take a quick overview of the current landscape. All these charts are based on a sample of investors that have been interviewed by LSN Research in 2016.

Firstly, what type of investors are currently looking into life science and health innovation deals? While venture capital and private equity remain a significant source of startup funds, we also speak with many major corporations in healthcare and their corporate VC arms, in addition to private and family office investors, angels, foundations, and others...


By Nono Hu, Director of Marketing, LSN

To bring LSN's Life Science Executive's Fundraising Manifesto toward a close, we provide some motivational advice and tactical reminders to help a fundraising CEO bring their outbound campaign to a successful resolution.

With illustrations and helpful mottos, this 'cheat sheet' chapter will help the reader find their way through the fundraising maze in good spirits. From how to stay optimistic during the tough times, to when to stop marketing to investors, this chapter has it covered.